78
Participants
Start Date
October 1, 2024
Primary Completion Date
June 30, 2027
Study Completion Date
December 30, 2027
befotertinib
Befotertinib will be administered orally at an initial dose of 75 mg once daily for 21 days, with escalation to 100 mg if tolerated. Treatment continues until disease progression, unacceptable toxicity, or withdrawal.
RECRUITING
2nd Affiliated Hospital, School of Medicine, Hangzhou
The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
UNKNOWN
Hunan Cancer Hospital - the Affiliated Cancer Hospital of Xiangya school of Medicine, Central South University
UNKNOWN
Taizhou Hospital
OTHER
West China Hospital
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER